NCT05445128 - Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 24, 2022

Primary Completion Date

December 8, 2022

Study Completion Date

February 2, 2023

Conditions

Sickle Cell Disease

Interventions

BIOLOGICAL

MGTA-145

MGTA-145 will be administered as an IV infusion

DRUG

Plerixafor

240 µg/kg administered subcutaneously

Trial Locations (3)

National Institutes of Health, Bethesda

St. Jude Children's Research Hospital, Memphis

Boston Children's Hospital, Boston